Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 27

1.

Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis.

Ailawadhi S, Parikh K, Abouzaid S, Zhou Z, Tang W, Clancy Z, Cheung C, Zhou ZY, Xie J.

Blood Adv. 2019 Oct 22;3(20):2986-2994. doi: 10.1182/bloodadvances.2019000308.

PMID:
31648322
2.

Lenalidomide maintenance post-transplantation in newly diagnosed multiple myeloma: real-world outcomes and costs.

Hari P, Ung B, Abouzaid S, Agarwal A, Parikh K.

Future Oncol. 2019 Oct 18. doi: 10.2217/fon-2019-0422. [Epub ahead of print]

3.
4.

Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry.

Rifkin RM, Jagannath S, Durie BGM, Narang M, Terebelo HR, Gasparetto CJ, Toomey K, Hardin JW, Wagner L, Parikh K, Abouzaid S, Srinivasan S, Kitali A, Zafar F, Abonour R.

Clin Ther. 2018 Jul;40(7):1193-1202.e1. doi: 10.1016/j.clinthera.2018.05.017. Epub 2018 Jul 23.

5.

The Importance of Economic Trade-offs in Cancer Drug Pricing.

Fonseca R, Peneva D, Clancy Z, Abouzaid S, Jena AB.

Mayo Clin Proc. 2018 Aug;93(8):976-979. doi: 10.1016/j.mayocp.2018.05.025. Epub 2018 Jun 23. No abstract available.

PMID:
29945732
6.

Assessing the Effect of Adherence on Patient-reported Outcomes and Out of Pocket Costs Among Patients With Multiple Myeloma.

Gupta S, Abouzaid S, Liebert R, Parikh K, Ung B, Rosenberg AS.

Clin Lymphoma Myeloma Leuk. 2018 Mar;18(3):210-218. doi: 10.1016/j.clml.2018.01.006. Epub 2018 Jan 31. Erratum in: Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):552.

7.

Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States.

Pelligra CG, Parikh K, Guo S, Chandler C, Mouro J, Abouzaid S, Ailawadhi S.

Clin Ther. 2017 Oct;39(10):1986-2005.e5. doi: 10.1016/j.clinthera.2017.08.010. Epub 2017 Sep 28.

8.

Real-World Treatment Patterns, Time to Next Treatment, and Economic Outcomes in Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide or Carfilzomib.

Chen CC, Parikh K, Abouzaid S, Purnomo L, McGuiness CB, Hussein M, Wade RL.

J Manag Care Spec Pharm. 2017 Feb;23(2):236-246. doi: 10.18553/jmcp.2017.23.2.236.

9.

Trends in overall survival and costs of multiple myeloma, 2000-2014.

Fonseca R, Abouzaid S, Bonafede M, Cai Q, Parikh K, Cosler L, Richardson P.

Leukemia. 2017 Sep;31(9):1915-1921. doi: 10.1038/leu.2016.380. Epub 2016 Dec 23.

10.

Cost of Treatment for Relapsed/Refractory Multiple Myeloma.

Abouzaid S, Gibson C, Nagarwala Y.

Am Health Drug Benefits. 2015 Dec;8(9):470. No abstract available.

11.

Cohort analysis assessing medical and nonmedical cost associated with obesity in the workplace.

Kleinman N, Abouzaid S, Andersen L, Wang Z, Powers A.

J Occup Environ Med. 2014 Feb;56(2):161-70. doi: 10.1097/JOM.0000000000000099.

PMID:
24451611
12.

Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study.

Agashivala N, Wu N, Abouzaid S, Wu Y, Kim E, Boulanger L, Brandes DW.

BMC Neurol. 2013 Oct 4;13:138. doi: 10.1186/1471-2377-13-138.

13.

Direct and indirect cost burden associated with multiple sclerosis relapses: excess costs of persons with MS and their spouse caregivers.

Parisé H, Laliberté F, Lefebvre P, Duh MS, Kim E, Agashivala N, Abouzaid S, Weinstock-Guttman B.

J Neurol Sci. 2013 Jul 15;330(1-2):71-7. doi: 10.1016/j.jns.2013.04.007. Epub 2013 May 3.

PMID:
23647840
15.
16.

Economic burden associated with extrapyramidal symptoms in a medicaid population with schizophrenia.

Abouzaid S, Tian H, Zhou H, Kahler KH, Harris M, Kim E.

Community Ment Health J. 2014 Jan;50(1):51-8. doi: 10.1007/s10597-012-9561-7. Epub 2012 Nov 16.

17.

Patient adherence to transdermal rivastigmine after switching from oral donepezil: a retrospective claims database study.

Tian H, Abouzaid S, Chen W, Kahler KH, Kim E.

Alzheimer Dis Assoc Disord. 2013 Apr-Jun;27(2):182-6. doi: 10.1097/WAD.0b013e318266fb02.

PMID:
22892648
18.

Health care utilization and costs among patients with AD with and without dysphagia.

Tian H, Abouzaid S, Sabbagh MN, Chen W, Gabriel S, Kahler KH, Kim E.

Alzheimer Dis Assoc Disord. 2013 Apr-Jun;27(2):138-44. doi: 10.1097/WAD.0b013e318258cd7d.

PMID:
22596081
19.

Resource utilization and costs associated with insomnia treatment in patients with major depressive disorder.

Tian H, Abouzaid S, Gabriel S, Kahler KH, Kim E.

Prim Care Companion CNS Disord. 2012;14(5). pii: PCC.12m01374. doi: 10.4088/PCC.12m01374. Epub 2012 Sep 27.

20.

Appropriate medication prescribing in elderly patients: how knowledgeable are primary care physicians? A survey study in Parma, Italy.

Maio V, Jutkowitz E, Herrera K, Abouzaid S, Negri G, Del Canale S.

J Clin Pharm Ther. 2011 Aug;36(4):468-80. doi: 10.1111/j.1365-2710.2010.01195.x. Epub 2010 Oct 19.

PMID:
21729112

Supplemental Content

Loading ...
Support Center